Synthetic Biologics Inc. (SYN) stock surging during pre-market. Let’s find out why?
Synthetic Biologics Inc. (NASDAQ: SYN) stock declined by 5% at last close while the SYN stock price surged by 2.58% in the pre-market trading session. Synthetic Biologics is a clinical-stage business that uses the microbiome to create medicines to prevent and cure GI illnesses in regions where there is a significant unmet need. >> 7 […]
How did Synthetic Biologics, Inc. (NYSE American: SYN) climb during premarket?
Clinical-stage company Synthetic Biologics, Inc. (NYSE American: SYN) develops therapeutics for gastrointestinal diseases. Its lead product candidates include SYN-004 that has completed Phase II clinical studies designed to degrade commonly used intravenous beta-lactam antibiotics that have been in use for years. Recent Performance In the recent session Company’s stock finished up 30.57% to $0.50. During […]
